Opko Health Inc. (OPK) CEO Buys $708,550.00 in Stock

Opko Health Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost acquired 185,000 shares of the stock in a transaction that occurred on Friday, February 9th. The shares were bought at an average cost of $3.83 per share, for a total transaction of $708,550.00. Following the completion of the transaction, the chief executive officer now directly owns 3,068,951 shares of the company’s stock, valued at approximately $11,754,082.33. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Phillip Md Et Al Frost also recently made the following trade(s):

  • On Wednesday, February 7th, Phillip Md Et Al Frost bought 78,000 shares of Opko Health stock. The stock was acquired at an average price of $4.22 per share, with a total value of $329,160.00.
  • On Monday, February 5th, Phillip Md Et Al Frost bought 50,000 shares of Opko Health stock. The stock was acquired at an average price of $4.14 per share, with a total value of $207,000.00.
  • On Friday, February 2nd, Phillip Md Et Al Frost bought 55,000 shares of Opko Health stock. The stock was acquired at an average price of $4.30 per share, with a total value of $236,500.00.
  • On Wednesday, January 31st, Phillip Md Et Al Frost bought 65,000 shares of Opko Health stock. The stock was acquired at an average price of $4.47 per share, with a total value of $290,550.00.
  • On Friday, January 26th, Phillip Md Et Al Frost bought 55,000 shares of Opko Health stock. The stock was acquired at an average price of $4.90 per share, with a total value of $269,500.00.
  • On Wednesday, January 24th, Phillip Md Et Al Frost bought 100,000 shares of Opko Health stock. The stock was acquired at an average price of $4.89 per share, with a total value of $489,000.00.
  • On Monday, January 22nd, Phillip Md Et Al Frost bought 100,000 shares of Opko Health stock. The stock was acquired at an average price of $4.40 per share, with a total value of $440,000.00.

Shares of Opko Health Inc. (NASDAQ OPK) opened at $3.88 on Monday. The company has a debt-to-equity ratio of 0.01, a current ratio of 1.66 and a quick ratio of 1.48. Opko Health Inc. has a one year low of $3.61 and a one year high of $8.92. The firm has a market cap of $2,170.00, a price-to-earnings ratio of -20.42 and a beta of 1.42.

Several institutional investors have recently modified their holdings of the company. Vanguard Group Inc. lifted its stake in shares of Opko Health by 1.1% in the second quarter. Vanguard Group Inc. now owns 26,618,758 shares of the biotechnology company’s stock worth $175,151,000 after buying an additional 296,757 shares during the last quarter. State Street Corp lifted its stake in shares of Opko Health by 3.9% in the second quarter. State Street Corp now owns 11,348,763 shares of the biotechnology company’s stock worth $74,671,000 after buying an additional 422,203 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in shares of Opko Health by 127.2% in the third quarter. Dimensional Fund Advisors LP now owns 4,003,643 shares of the biotechnology company’s stock worth $27,466,000 after buying an additional 2,241,103 shares during the last quarter. Harel Insurance Investments & Financial Services Ltd. lifted its stake in shares of Opko Health by 83.7% in the third quarter. Harel Insurance Investments & Financial Services Ltd. now owns 2,579,950 shares of the biotechnology company’s stock worth $17,698,000 after buying an additional 1,175,726 shares during the last quarter. Finally, IFP Advisors Inc lifted its stake in shares of Opko Health by 37.1% in the fourth quarter. IFP Advisors Inc now owns 1,963,601 shares of the biotechnology company’s stock worth $9,622,000 after buying an additional 531,088 shares during the last quarter. Institutional investors and hedge funds own 22.68% of the company’s stock.

A number of analysts have issued reports on the stock. BidaskClub cut shares of Opko Health from a “sell” rating to a “strong sell” rating in a research note on Wednesday, January 10th. Zacks Investment Research cut shares of Opko Health from a “hold” rating to a “sell” rating in a research note on Thursday, January 11th. Finally, Cantor Fitzgerald set a $20.00 target price on shares of Opko Health and gave the company a “buy” rating in a research note on Wednesday, October 25th. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating to the company. The stock has a consensus rating of “Hold” and an average target price of $13.34.

TRADEMARK VIOLATION WARNING: This piece was originally posted by American Banking News and is owned by of American Banking News. If you are accessing this piece on another domain, it was copied illegally and reposted in violation of United States & international copyright laws. The correct version of this piece can be read at https://www.americanbankingnews.com/2018/02/12/opko-health-inc-opk-ceo-buys-708550-00-in-stock.html.

About Opko Health

OPKO Health, Inc is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations.

Insider Buying and Selling by Quarter for Opko Health (NASDAQ:OPK)

Receive News & Ratings for Opko Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply